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After more than 150 years of a recognised link between cancer and vascular thromboembolic events (VTE), and despite a greatly
improved understanding of its pathophysiology, epidemiology and treatment, the management of patients with cancer and VTE is still
limited. Limitations can be related to the thromboembolism itself, the underlying cancer, or to the management process. There is
significant literature that deals with the first two, but very little regarding the systems we use, or how the inadequacies in
documentation, identification and classification of VTE affect the cancer patients themselves. This review aims to raise awareness of
this neglected area and stimulate research that may lead to improvements in patient care.
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The relationship between thrombosis and cancer was studied by
Trousseau in the nineteenth century; however, limitations in
clinical management persist despite subsequent therapeutic and
diagnostic strides.
The first limitation observed is that patients still die from
clinically apparent vascular thromboembolic event (VTE), even if
diagnosed and treated appropriately, irrespective of whether it is
cancer related or not.
The second limitation lies with the complex management
challenges that result from the cancer itself, increasing the risk
of a poorer VTE outcome even if diagnosed and treated
appropriately. The underlying cancer may also influence the
perception of the treating physician, affecting decision making for
a patient with cancer-related VTE. This issue is exacerbated by the
tendency to practise suboptimal management despite best
evidence.
Finally, the third limitation arises from the clinical features of
VTE that can render it ‘invisible’ using current processes, which
include ‘index of clinical suspicion’ and diagnostic and reporting
tools. This could lead to a ‘perception gap’, which compounds the
first two limitations.
This review provides a summary of existing evidence, discusses
gaps in our understanding and suggests avenues of research.
We present the topic under two themes: (A) Visible VTE and (B)
Invisible VTE.
(A) Visible VTE
Limitations because of thrombosis Vascular thromboembolic
events carry a risk of death, whether they are cancer-related or
not (Summary Box 1). Regression models have been developed for
pulmonary embolism (PE), myocardial infarction (MI) and
cerebrovascular accident (CVA) in the general acute medical
population from which mortality-prediction tools are derived.
These tools highlight that visible thrombosis (i.e., diagnosed),
despite presumably optimal treatment, can cause significant
mortality.
In addition, the manifestation of one-type VTE is a harbinger of
further vascular thromboembolic events, for example, during the
first year after a PE there is a threefold increased risk of CVA and a
2.5-fold risk of MI (Sørensen et al, 2007). Thrombosis-affected
cancer patients treated with anticancer therapies in an adjuvant
setting will survive long enough to experience this ‘domino’ effect.
Limitations because of cancer
Cancer related: Vascular thromboembolic event in patients with
cancer can be difficult to manage due to an increased risk of
bleeding and further episodes of VTE despite anticoagulation,
particularly with warfarin (Prandoni et al, 2002). These risks
increase with progressive cancer (Prandoni et al, 2002), and
clinical decisions can be difficult in patients for whom the focus of
treatment is palliative, but who are not imminently dying (Johnson
and Sherry, 1997; Noble, 2007). The risks worsen with advanced
disease not only because of ulceration or venous compression by
tumour but also because of significant disseminated intravascular
coagulation (Johnson et al, 1999b). Patients may also have
thrombocytopenia secondary to treatment or marrow infiltration.
Therapy related: Anticancer therapies increase the risk of VTE.
However, apart from low level evidence base recommendations for
myeloma patients receiving thalidomide and linalinomide, there is
no clear evidence-based guidance regarding thromboprophylaxis.
Clinician related: There is an ambivalent attitude to VTE in
cancer setting, which may lead to underdiagnosis and under-
treatment. It may be commented, ‘a big PE is a nice way to go’
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assumption (Havig, 1977). The unpredictable nature of recurrent
VTE may also be a problem for patients for whom ‘last goals’ are
important, and a sudden but unpleasant death can contribute to
family distress in bereavement. As clinical decision making moves
from traditional paternalism towards patient centre, we need to
consider both RCT evidence base for management and patient
view of what they consider acceptable. Significant differences may
exist between the health professional and the patient with regard to
risks and benefits.
It is recognised that suboptimal management occurs despite best
evidence. Knowledge of research evidence is rarely enough to
change practice (NHS Centre for Reviews and Dissemination,
1999) and other factors that affect clinical decision making. Level 1
evidence-based guidelines for secondary prevention of VTE in
cancer patients, including those with advanced disease, recom-
mending long-term treatment with low-molecular-weight heparin
(LMWH), have been published (Lyman et al, 2007; Noble et al,
2008b). Despite this, a UK VTE Registry’s most recent report noted
that only 9% of patients received LMWH for more than 30 days
and only 5% for more than 90 days (VERITY Venous Thrombo-
embolism Registry, 2007). The use of warfarin persists in cancer
patients despite the risks of polypharmacy, liver metastases,
low albumin, inadequate nutritional status and chemotherapy
scheduling.
Limitations because of current recognition processes The ambiva-
lent attitude regarding the significance of cancer-related VTE
may affect the ‘index of suspicion’ and willingness to investigate
a possible VTE, even when clinically apparent. It may also be
reflected in the recording process in clinical trials, which in turn is
reflected in subsequent evidence-based clinical guidance, leading to
a vicious cycle of poor recognition and suboptimal management.
Limitations due to recording of VTE in clinical trials: Highly
sensitive, accurate and minimally invasive imaging techniques
such as spiral computed tomography should improve the detection
of VTE. VERITY figures reflect this, but research studies, at least
until recently, do not. In a systematic review of 19 major advanced
pancreatic cancer (APC) randomised trials published from 1997 to
2007, including 6212 patients (Sgouros and Maraveyas, 2008), VTE
incidence was inconsistently reported.
Possibly, trial eligibility criteria select patients in whom the VTE
incidence is truly low. Thrombosis may occur in the diagnosis
phase of pancreatic cancer, rendering the patient ineligible for
treatment trials. Patients with cardiovascular events during the
preceding 6 months may also be excluded. However, it remains
surprising that this selected population, with a tumour known to
be highly thrombogenic, apparently has a negligible reported VTE
incidence during a median survivorship of 6 months. The more
likely explanation is that VTE is not seen as a drug-related adverse
event. Therefore, the data may be recorded, but not reported in the
publication. The primary published results of the NCI-CTG PA.3
trial (Moore et al, 2007a) did not mention VTE incidence, but on
request, figures of 14% all-type VTE were reported (Moore et al,
2007b). Vascular thromboembolic events formally reported as the
cause of death in only two of 1447 patients (0.1%) (Sgouros
and Maraveyas, 2008). Even if a significant number of VTE have
silent or ‘sudden death’ presentations, such a low incidence of
reported VTE-related death is surprising.
Limitations due to the method of recording VTE in clinical
trials: Binary reporting, i.e. VTE present or absent (Moore et al,
2007b), is better than none at all, but does not capture clinical
complexities. A grading system documenting type, complexity and
outcome of VTE is desirable. We suggest that the currently used
CTCAE tool (Common Terminology Criteria for adverse events
version 3.0; the National Cancer Institute (NCI) Cancer Therapy
Evaluation Programme (CTEP)) for VTE (Figure 1) attempts to
grade, but is wholly inadequate and has no evidence base. For
example, a 50-year-old patient with an asymptomatic, small PE
found on interval imaging has a different outcome risk com-
pared with the 70-year-old patient with a saddle embolus and
circulatory–neurological compromise, but both would be CTCAE
grade 4.
There are a number of scoring systems for PE outcome in the
general medical literature. One prognostic model (Aujesky et al,
2006) classifies PE patients into five risk classes (I–V), with
different cumulative 90-day mortalities, from 0% in class I to
24.4% in class V.
Some of the immediate mortality from a diagnosed VTE may be
captured as a CTCAE grade 5 event within ongoing serious adverse
event (SAE) reporting, but much mortality or morbidity can be
misattributed and subsequent deaths or morbidity are unlikely to
be recorded as VTE related. A grading system that captures clinical
consequence is urgently needed.
Limitations in attributing causality to cancer treatments:
Although almost all systemic cancer treatments can increase the
risk of VTE, the commonly reported causality of VTE as an SAE in
trials remains cancer. Therefore, the incidence of VTE for some
Box 1 Visible VTE challenges
K Limitations because of the thrombosis
J Natural history of VTE includes mortality even in non-cancer patients
despite current best treatment
K Limitations because of the cancer
J The cancer patient (e.g., hemorrhage from primary, effect of
secondaries e.g., liver, marrow, performance status compromise)
J Clinician’s perception of benefit of treatment
J Delay in implementing evidence-based standards
K Limitations because of clinical processes and clinical trial method
J Low-clinical index of suspicion and clinician reluctance to investigate
J Binary recording is insufficient and current CTCAE grading tool not fit
for purpose in clinical trials
J The need to accept VTE as a potential treatment-related SAE in
clinical trials
J The need for validated scoring systems that relate grade to outcome
in clinical trials and clinical practice
J The need for CRF design to be able to capture the ongoing nature of
a VTE SAE in clinical trials.
J The need for research to understand the significance of splanchnic
DVT in cancer, especially in APC.
GRADE Adverse event
  5   4   3   2   1
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Figure 1 Current CTCAE grading system used for thromboembolism.
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underestimated, only becoming apparent through pharmacovigi-
lance review. As the pro-thrombotic tendency of thalidomide had
already been exposed, (Bennett et al, 2006) this was immediately
recognised with linalinomide and included in the licensed product
pamphlet. However, a prolonged post-market pressure was
exerted before this was included in the thalidomide drug
information too.
It is a recent appreciation, rather than during drug development,
that conventional chemotherapy agents increase VTE risk by 4–6
fold (Ogren et al, 2006). We therefore have little comparative VTE
risk data for commonly used agents or for the effect of different
ways of administration on this risk. The need for prospective data
can be shown; ECF chemotherapy for gastoesophageal cancer
produced an incidence of 17.7% VTE in an RCT setting (Starling
et al, 2007), whereas a retrospective database analysis of earlier
RCTs using the same regimen from the same group presented a
year earlier recorded only 3%.
Newer anti-angiogenic agents are being subjected to greater
scrutiny, possibly because VTE prominence was recognised during
developmental work and also, perhaps, because of potentially large
liability damages. Trials with bevacizumab, for example, have
recorded VTE incidence more carefully (Kindler et al, 2005).
Consequences of visible VTE
Malignancy-related VTE reduces survival (Alcalay et al, 2006;
Mandala ` et al, 2007). Most studies are retrospective registry
related, but the striking effect of VTE on APC can be seen most
clearly in the sub-analysis of the NCI-CTG PA3 trial (Moore et al,
2007b). The detrimental effect of VTE on survival is greater than
the beneficial impact of erlotinib and has the same impact as
performance status and stage. Vascular thromboembolic event is
more common in advanced stages of cancer but confers a worse
prognosis even if corrected for pathological stage. Stage-related
distinctions in APC are difficult, but in colorectal cancer (CRC), in
which the majority of patients have accurate pathological staging,
there is increased VTE-related mortality irrespective of stage
(Alcalay et al, 2006). The greatest impact of VTE was seen in Dukes
A (TNM stage I) patients despite potentially less arduous surgery
and no chemotherapy. It is suggested that the underlying
malignancy has a more aggressive course, despite no difference
in conventional prognostic indicators such as histological grade.
However, the separation of the curves within 100 days after VTE is
in contrast to the expected natural history of resected Dukes A
cancer. We think this raises significant doubt that the VTE-related
poorer prognosis is simply because VTE is the preserve of
advanced disease or is an epiphenomenon of more aggressive
disease. Vascular thromboembolic event can have lethal conse-
quences and, although rarer in early-stage disease, the impact is
greater in such patients. This chimes with the sub-analyses of
existing trials (Akl et al, 2007) of LMWH in cancer, suggesting that
patients with better prognoses received greater survival benefit
from LMWH. In advanced disease, it may be more difficult to
discern the contribution of VTE to mortality over and above that
of cancer. Stage IV CRC patients from the above study had no
statistically significant different survival, despite a trend for worse
outcome (Alcalay et al, 2006).
(B) Invisible VTE
Epidemiological and pathological evidence The true prevalence of
VTE is underestimated because many are clinically unapparent
(Summary Box 2). Pre-mortem studies indicate that when a
proximal DVT is diagnosed, PE has occurred in up to 50% of
patients, although only 33–40% are symptomatic (Khorana and
Fine, 2004; Ogren et al, 2006; Cronin et al, 2007). Postmortem and
epidemiological studies in cancer patients have established VTE
both as a common coexisting entity and as a direct cause of death.
An autopsy study investigating the presence of VTE in patients
with various types of cancer, including 441 patients with APC,
found that 42% of the APC patients had PE, the sole cause of death
in 14% of patients (Ogren et al, 2006). This study verifies other data
identifying APC patients to be at high risk of VTE (Maraveyas et al,
2007). The development of biological markers predictive
of VTE risk would be a major step forward. Some recent work in
early stages suggests that cancer tissue levels of tissue factor (TF) or
circulating TF antigen may hold such promise (Khorana et al, 2007).
The risk of VTE increases with advanced tumour. A study of
consecutive admissions to a palliative care unit showed evidence of
lower limb DVT in 135 out of 258 patients (52%; 95% confidence
interval 46–58%) (Johnson et al, 1999a). Only 22 patients (9%)
had clinically recognised VTE and confirmation with imaging.
Second, there is evidence that VTE mimics other conditions and
thus is unrecognised rather than truly asymptomatic. Postmortem
studies confirm a persistent poor pre-mortem recognition of PE
(Cronin et al, 2007), ranging from 11% in the 1950s to 45% in the
1990s. Although reliable twenty-first century data are unavailable,
it is likely that more than half the patients, including those with
cancer, dying from PE today are undiagnosed pre-mortem.
Incidentally discovered VTE The high-resolution CT scanner has
produced the phenomenon of incidental VTE, found in up to 1.5%
of routine helical CT scans, increasing to 2.6–3.4% in patients with
cancer and as high as 6.3% for all-type VTE (Cronin et al, 2007).
Some of these may remain silent if left untreated; however, some
will become symptomatic with either an atypical presentation or
misattributed to the underlying morbidity. There may be an
opportunity to initiate effective treatment, but some may result in
an unexpected mortality through persistent misrecognition or
from sudden death. Incidental PE is not necessarily clinically
insignificant and a lethal PE is not always preceded by a ‘silent’
phase; Havig’s postmortem study showed that two-thirds of
the abruptly dead had had symptoms of ‘advertising emboli’
(Havig, 1977).
Splanchnic thrombosis is another poorly understood entity and
rarely clinically suspected. Most studies are dominated by retro-
spective surgical series, primarily in benign disease. Thus, we
know little about the incidence, natural history, prognosis or
management of these events in cancer patients. It may be more
common than previously thought, with more incidental splanchnic
DVTs found than ileofemoral or common iliac DVTs during
staging CT (Sgouros and Maraveyas, 2008) in patients with APC.
Thus, the natural history of splanchnic DVT, its potential role as a
Box 2 Invisible VTE challenges
K Limitations because of the thrombosis
J VTE can be ‘silent’
J Natural history of silent VTE unknown
’ Undiagnosed does not mean insignificant
K Limitations because of the cancer
J Underlying cancer can obscure symptoms of VTE
’ Undiagnosed does not mean insignificant
J Type and stage of underlying cancer may dissuade clinician from
extensive diagnostic work-up
K Limitations because of clinical processes and clinical trial method
J Incidental VTE
’ What is the contribution to mortality and morbidity of
incidental VTE?
J When to investigate atypical symptoms, for example, fatigue, for PE?
J Natural history of silent VTE in cancer is unknown
’ Does it need treatment?
’ Grading and risk assessment unknown
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haemorrhage, bowel insufficiency and necrosis, needs further
elucidation.
Is incidental silent? The difference between the terms ‘incidental’
and ‘silent’ is pertinent. A VTE may be discovered incidentally, but
may not be silent, as confirmation may lead to discovery of
symptoms. A silent VTE is one that has no symptoms or signs that
could reasonably be attributable to VTE even in retrospect.
A retrospective case–control study of (O’Connell et al, 2006) 59
patients with incidental PE showed that patients with PE were
significantly more likely to be fatigued (odds ratio of 4.82
(P¼0.0002)). Breathlessness, a classic symptom of PE, was seen
in a minority of cases (22 vs 8%, P¼0.02). However, as this study
included cancer patients at different stages of diagnosis and
treatment, it is difficult to discern which symptoms are due to
cancer or to its treatment, especially when the symptoms may be
atypical of PE and the time of embolism is unknown.
Consequences of invisible VTE
Hidden mortality We have coined the term ‘early death burden’
(EDB) to describe an observed early (12 week) survivorship
shortfall in patients enrolled in randomised phase III trials
(Sgouros and Maraveyas, 2008). Early death burden seems most
conspicuous in advanced APC; 23% compared with under 4% in
metastatic CRC. The conventional explanation is that this is due to
the ‘aggressive’ nature of APC (short survival time and reduced
chemosensitivity of APC compared with CRC). However, given the
eligibility criteria designed to enter patients with an expected
survival of 3 months or more by specifying adequate end-organ
function and good performance status, it is no more likely that
almost a quarter of participating APC patients will die of disease
progression within 12 weeks than those with CRC. Early death
burden may be favourably affected by systemic treatment efficacy
or conversely exacerbated by some of the anticancer treatments
themselves. Some of it will be caused by ‘early toxic death’ of the
treatment and some will reflect cancer-related deaths from
infection or organ failures. However, despite these factors, we
speculate that there is still a shortfall in expected survival in APC,
which we suggest reflects the existence of significant unappreciated
VTE. Vascular thromboembolic event-driven EDB is likely to be a
mixture of invisible events, that is, sudden death with no
postmortem or those who die with misattributed symptoms, and
events from ‘visible’ VTE, the cause of death being mislabeled as
‘cancer progression’. Such hidden events may be prevented by
LMWH (in a secondary prevention dose), and recruitment into a
phase IIb trial of thromboprevention in APC with EDB as a
secondary endpoint is now closed (EUDRACT No.:111-111111-11).
Data from this study will help confirm or refute our concerns.
CONCLUSION
The presence of cancer and its treatment make diagnosis and
management of VTE difficult. There are gaps in our understanding
regarding the clinical impact of VTE in a cancer patient and the
interplay between cancer, its treatment and thrombosis, which
could lead to ambiguity and complacency over its recognition,
diagnosis, treatment and recordable outcome. We suggest that this
could contribute to preventable morbidity and mortality of cancer
patients, especially in those with highly thrombogenic tumours.
We hope to cast some doubt on the explanation that the
survivorship shortfall in patients with VTE is solely an epipheno-
menon of a more aggressive malignancy or chemo-resistant
tumours. We have made some suggestions that may help direct
further efforts to inform this field (Box 3).
A clinically relevant grading system for recording VTE in
cancer trials, systematic study of the clinical impact of co-
incidental/silent VTE and continued research into optimal
anticoagulation are urgently needed to close some of these
gaps. A higher level of clinical suspicion, a greater understanding
of the complexities of cancer-related VTE, with strategies for
prevention, recognition and management, and research into
developing biological predictive markers of VTE are required to
improve the current situation. If not, Trousseau’s legacy will
continue, exposing the shortcomings of the contemporary clinical
method.
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